The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Antisense & RNAi Therapeutics Market Between 2026 And 2030?
The antisense & rnai therapeutics market size has seen swift expansion in recent years. It is projected to increase from $1.93 billion in 2025 to $2.17 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.6%. This historical growth is attributable to the early adoption of antisense therapies, initial rnai research breakthroughs, the development of oligonucleotide synthesis techniques, growing demand for targeted therapeutics, and investments in biotech research.
The antisense & rnai therapeutics market is projected to experience substantial expansion over the coming years. This market is anticipated to reach $3.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.9%. Factors contributing to this growth during the forecast period include advances in delivery technologies, the broadening scope of precision medicine, integration with AI-driven drug discovery, a rise in RNAi-based clinical trials, and increased healthcare investments within emerging markets. Key trends expected during the same period encompass targeted gene silencing, innovative delivery mechanisms, personalized therapeutic approaches, nucleic acid stabilization techniques, and progress in regulatory and clinical aspects.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
What Key Drivers Are Influencing The Growth Of The Antisense & RNAi Therapeutics Market?
The increasing incidence of coronary artery diseases, neurodegenerative conditions, and infectious ailments is anticipated to fuel the demand within the antisense & RNAi therapeutics market. Gene silencing methods, such as RNA interference and antisense oligonucleotides, find application in addressing diverse neurodegenerative diseases through the correction of faulty genes. For example, a report from January 2024 by the American Heart Association, a US-based organization, indicated that the age-adjusted mortality rate from cardiovascular diseases rose to 233.3 per 100,000, showing a 4.0% increase compared to the prior year. Consequently, the expanding occurrence of numerous neurodegenerative conditions and infectious illnesses is set to propel the expansion of the antisense & RNAi therapeutics market.
Which Market Segments Are Examined In The Antisense & RNAi Therapeutics Market Study?
The antisense & rnai therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics
2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides
Which Trends Are Influencing The Antisense & RNAi Therapeutics Market?
Major companies operating in the antisense & RNAi therapeutics market are engaging in strategic initiatives, such as collaborations and partnerships, to sustain their presence in the increasingly competitive market. A strategic collaboration is a business approach where two or more companies work together to achieve a common goal or objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company providing services for peptide discovery, partnered with SanegeneBio Inc., a UK-based company focused on developing novel RNAi-based medicines, to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown, with the aim of developing a portfolio of advanced RNAi therapeutics. This collaboration includes hit identification and cell-based internalization studies, granting Sanegene the option to further develop the hits derived from the screening activities, by leveraging Orbit’s proprietary technology for rapid peptide lead discovery. Orbit Discovery’s unique peptide display engine allows for the screening of large peptide libraries, leading to faster discovery times for relevant peptide leads based on affinity and functional screens.
Who Are The Primary Competitors In The Antisense & RNAi Therapeutics Market?
Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen İlaç ve Sağlık Ürünleri A.Ş., Egypt Otsuka Pharmaceutical
Read the full antisense & rnai therapeutics market report here:
Which Region Is Expected To Register The Fastest Growth In The Antisense & RNAi Therapeutics Market?
North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Antisense & RNAi Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp
Browse Through More Reports Similar to the Global Antisense & RNAi Therapeutics Market 2026, By The Business Research Company
Antisense And Rnai Therapeutics Market Report 2026
Rna Targeting Small Molecules Therapeutics Market Report 2026
Mrna Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model